The effects of captopril on lipopolysaccharide-induced sickness behaviors in rats

Document Type: Original Article

Authors

1 Division of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Physiology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran

3 Department of Physiology, Esfarayen Faculty of Medical Sciences, Esfarayen, Iran

4 Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5 Neuroscience Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran

6 Department of Physiology, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran

7 Department of Electrical Engineering, Faculty of Montazeri, Khorasan Branch, Technical and Vocational University (TVU), Mashhad, Iran

Abstract

Neuro-immune mediators play an important role in the development of sickness behaviors. In the present study, the effect of captopril on sickness behaviors caused by lipopolysaccharide (LPS) was studied in the rats. The animals were randomized into the following groups: control, sham, 10 mg kg-1 captopril - LPS (Capto 10-LPS), 50 mg kg-1 captopril - LPS (Capto 50-LPS), and 100 mg kg-1 captopril - LPS (Capto 100-LPS). Behavioral tests including open-field (OF), elevated plus maze (EPM) and forced swimming (FS) test were performed, and the serum level of interleukin-6 (IL-6) was assessed. In OF, the number of crossings in the central zone in Capto 10-LPS, Capto 50-LPS, and Capto 100-LPS groups was higher than that of the sham group. In EPM, the open arm entry numbers in the sham group were lower compared to the control group. Furthermore, pretreatment by captopril increased the entries to the open arms. In FS test, the immobility time of the sham group was longer than that of the control group. In Capto 10-LPS, Capto 50-LPS, and Capto 100-LPS groups, immobility was shorter compared to the sham group. In addition, the IL-6 level was higher in the sham group compared to the control group, and treatment with 50 and 100 mg kg-1 of captopril restored the IL-6 level in comparison with the sham group. Results confirmed that pretreatment with captopril ameliorated LPS-caused sickness behaviors and attenuated IL-6 as an inflammatory marker in the rats.

Keywords

Main Subjects

 

  1. Hosseini M, Alaei HA, Headari R, et al. Effects of microinjection of angiotensin II and captopril into nucleus accumbens on morphine self-administration in rats. Indian J Exp Biol 2009; 47(5): 361-367.
  2. Abareshi A, Anaeigoudari A, Norouzi F, et al. Lipopolysaccharide-induced spatial memory and synaptic plasticity impairment is preventable by captopril. Adv Med 2016.doi: 10.1155/2016/7676512.
  3. Hosseini M, Sharifi MR, Alaei H, et al. Effects of angiotensin II and captopril on rewarding properties of morphine. Indian J Exp Biol 2007; 45(9): 770-777.
  4. Gard PR. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol 2002; 438(1-2): 1-14.
  5. Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J Mol Med 2008; 86(6): 715-722.
  6. Braszko JJ, Karwowska-Polecka W, Halicka D, et al. Captopril and enalapril improve cognition and depressed mood in hypertensive patients. J Basic Clin Physiol Pharmacol 2003; 14(4): 323-343.
  7. Chang Y, Wei W. Angiotensin II in inflammation, immunity and rheumatoid arthritis. Clin Exp Immunol 2015; 179(2):137-145.
  8. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11(6): 194-205.
  9. Shimizu H, Miyoshi M, Matsumoto K, et al. The effect of central injection of angiotensin-converting enzyme inhibitor and the angiotensin type 1 receptor antagonist on the induction by lipopolysaccharide of fever and brain interleukin-1beta response in rats. J Pharmacol Exp Ther 2004; 308(3): 865-873.
  10. Benicky J, Sánchez-Lemus E, Pavel J, et al. Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol 2009; 29(6-7):781-792.
  11. Burton MD, Sparkman NL, Johnson RW. Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharide-induced sickness behavior. J Neuroinflammation 2011; 8:54. doi: 10.1186/1742-2094-8-54.
  12. Maes M, Berk M, Goehler L, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012; 10(1):66. doi: 10.1186/1741-7015-10-66.
  13. Maes M, Kubera M, Obuchowiczwa E, et al. Depression’s multiple comorbidities explained by (neuro) inflammatory and oxidative and nitrosative stress pathways. Neuro Endocrinol Lett 2011; 32:7-24.
  14. Hosseini M, Zakeri S, Khoshdast S, et al. The effects of Nigella sativa hydro-alcoholic extract and thymoquinone on lipopolysaccharide-induced depression like behavior in rats. J Pharm Bioallied Sci 2012; 4(3): 219-225.
  15. Sharp LK, Lipsky MS. Screening for depression across the lifespan. Am Fam Physician 2002; 66(6):1001-1008.
  16. Dantzer R, O'Connor JC, Lawson MA, et al. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011; 36(3): 426-436.
  17. Janssen DG, Caniato RN, Verster JC, et al. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010; 25(3): 201-215.
  18. Swiergiel AH, Dunn AJ. Effects of interleukin-1β and lipopolysaccharide on behavior of mice in the elevated plus-maze and open field tests. Pharmacol Biochem Behav 2007; 86(4): 651-659.
  19. Mullington J, Korth C, Hermann DM, et al. Dose dependent effects of endotoxin on human sleep. Am J Physiol Regul Integr Comp Physiol 2000; 278(4): 947-955.
  20. Abareshi A, Hosseini M, Beheshti F, et al. The effects of captopril on lipopolysaccharide induced learning and memory impairments and the brain cytokine levels and oxidative damage in rats. Life Sci 2016; 167: 46-56.
  21. Zhu L, Wei T, Gao J, et al. Salidroside attenuates lipopolysaccharide (LPS) induced serum cytokines and depressive-like behavior in mice. Neurosci Lett 2015; 606:1-6.
  22. Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord 2014; 169:15-20.
  23. Kang A, Hao H, Zheng X, et al. Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy. J Neuroinflammation. 2011;8:100. doi: 10.1186/1742-2094-8-100.
  24. Gao HM, Jiang J, Wilson B, et al. Microglial activation‐mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002; 81(6): 1285-1297.
  25. Dunn AJ, Wang J, Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 1999; 461: 117-127.
  26. Barua CC, Haloi P, Saikia B, et al. Zanthoxylum alatum abrogates lipopolysaccharide-induced depression-like behaviours in mice by modulating neuroinflammation and monoamine neurotransmitters in the hippocampus. Pharm Biol 2018; 56(1): 245-252.
  27. Yang TY, Jang EY, Ryu Y, et al. Effect of acupuncture on Lipopolysaccharide-induced anxiety-like behavioral changes: involvement of serotonin system in dorsal Raphe nucleus. BMC Complement Altern Med 2017;17(1): 528. doi: 10.1186/s12906-017-2039-y.
  28. Depino AM. Early prenatal exposure to LPS results in anxiety- and depression-related behaviors in adulthood. Neuroscience 2015; 299: 56-65.
  29. Bluthé R.M, Dantzer R, Kelley KW. Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res 1992; 573(2): 318-320.
  30. Piser TM. Linking the cytokine and neurocircuitry hypotheses of depression: A translational framework for discovery and development of novel anti-depressants. Brain Behav Immun 2010; 24(4): 515-524.
  31. Azizi-Malekabadi H, Pourganji M, Zabihi H, et al. Tamoxifen antagonizes the effects of ovarian hormones to induce anxiety and depression-like behavior in rats. Arq Neuropsiquiatr 2015; 73(2): 132-139.
  32. Hritcu L, Gorgan LD. Intranigral lipopolysaccharide induced anxiety and depression by altered BDNF mRNA expression in rat hippocampus. Prog Neuro-psychopharmacol Biol Psychiatry 2014; 51: 126-132.
  33. Gard, PR, Mandy A, Sutcliffe MA. Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. Biol Psychiatry 1999; 45(8):1030-1034.
  34. Hou DR, Wang Y, Zhou L, et al. Altered angiotensin-converting enzyme and its effects on the brain in a rat model of Alzheimer disease. Chin Med J (Engl) 2008; 121(22): 2320-2323.
  35. Tota S, Nath C, Najmi AK, et al. Inhibition of central angiotensin converting enzyme ameliorates scopolamine induced memory impairment in mice: role of cholinergic neurotransmission, cerebral blood flow and brain energy metabolism. Behav Brain Res 2012; 232(1): 66-76.
  36. Neamati A, Chaman F, Hosseini M, et al. The effects of Valeriana officinalis L. hydro-alcoholic extract on depression like behavior in ovalbumin sensitized rats. J Pharm Bioallied Sci 2014; 6(2): 97-103.
  37. von Bohlen und Halbach O, Albrecht D. The CNS renin-angiotensin system. Cell Tissue Res 2006; 326(2): 599-616.
  38. Saab YB, Gard PR, Yeoman MS, et al. Renin-angiotensin-system gene polymorphisms and depression. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(5):1113-1118.
  39. Villar-Cheda B, Dominguez-Meijide A, Valenzuela R, et al. Aging-related dysregulation of dopamine and angiotensin receptor interaction. Neurobiol Aging 2014; 35(7):1726-1738.
  40. Labandeira-García JL, Garrido-Gil P, Rodriguez-Pallares J, et al. Brain renin-angiotensin system and dopaminergic cell vulnerability. Front Neuroanat 2014; 8: 67.
  41. Georgiev V, Stancheva S, Getova D, et al. Effects of angiotensin II on brain monoamines in nonhypoxic and hypoxic mice. Pharmacol Biochem Behav 1995; 50(3):457-461.
  42. Georgiev VP, Lazarova M.B, Kambourova TS. Further evidence for the interactions between angiotensin II and GABAergic transmission in pentylenetetrazol kindling seizures in mice. Neuropeptides 1995; 28(1): 29-34.
  43. Robbins ME, Zhao W, Garcia-Espinosa MA, et al. Renin-angiotensin system blockers and modulation of radiation-induced brain injury. Curr Drug Targets 2010; 11(11):1413-1422.
  44. Ming, Z, Sawicki G, Bekar LK. Acute systemic LPS-mediated inflammation induces lasting changes in mouse cortical neuromodulation and behavior. Neurosci Lett 2015; 590: 96-100.        
  45. Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35(6): 881-900.
  46. Watanabe T, Hashimoto M, Wada M, et al. Angiotensin-converting enzyme inhibitor inhibits dehydration-enhanced fever induced by endotoxin in rats. Am J Physiol Regul Integr Comp Physiol 2000; 279(4): 1512-1516.
  47. Watanabe K, Taniguchi M, Miyoshi M, et al. Effects of central injection of angiotensin-converting-enzyme inhibitor and angiotensin type 1 receptor antagonist on the brain NF-kappaB and AP-1 activities of rats given LPS. Peptides 2006; 27(6): 1538-1546.
  48. Hao XQ, Zhang HG, Yuan ZB, et al. Prenatal exposure to lipopolysaccharide alters the intrarenal renin–angiotensin system and renal damage in offspring rats. Hypertens Res 2010; 33(1): 76-82.
  49. Kang YM, Ma Y, Zheng JP, et al. Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension. Cardiovasc Res 2009; 82(3): 503-512.
  50. Jenkins TA, Chai SY, Mendelsohn FA. Upregulation of angiotensin II AT1 receptors in the mouse nucleus accumbens by chronic haloperidol treatment. Brain Res 1997; 748(1-2):137-142.